269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details
臨床試験数 : 23 / 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03137160 (ClinicalTrials.gov) | May 4, 2017 | 27/4/2017 | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Ixekizumab | Ohio State University | Eli Lilly and Company | Completed | 18 Years | N/A | All | 5 | Phase 2 | United States |